Eli Lilly has announced a significant price reduction for its popular weight-loss drug, Zepbound, in the United States by offering higher doses in vials. This new pricing undercuts the cost of the injector pen versions by $150, marking a strategic move to increase demand amid competitive market pressures.
About the Author
